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INTRODUCTION
Over the past several years, a number of groups have
reported on the outcome of patients who received granulo-
cyte colony-stimulating factor (G-CSF)–mobilized periph-
eral blood progenitor cells (PBPCs) during HLA-matched
allogeneic transplantation [1-5]. These results have consis-
tently shown that patients engraft earlier with this product
than historically treated patients receiving bone marrow and
that, whereas engraftment is markedly improved after
administration of growth factors, it is not dependent on this.
Patients receiving PBPCs have an incidence of acute graft-
versus-host disease (aGVHD) of 14% to 70%, which is sur-
prising given the large number of T cells found in the
product. The incidence of chronic GVHD (cGVHD) after
PBPC infusion is approximately 70% to 80% compared
with 40% to 50% with conventional bone marrow [6,7].
This increased incidence of cGVHD after PBPC infusion is
a substantial barrier to using this product.
Several large ongoing clinical trials are underway to
compare the outcome of patients treated with either G-CSF–
mobilized PBPCs or unmanipulated bone marrow in allo-
geneic transplantation. Only 2 small published reports and
1 recent presentation, however, describe the outcome of
patients who received G-CSF–stimulated bone marrow
[1,8,9]. Previous reports in the autologous setting have shown
that engraftment of neutrophils is similar in patients receiv-
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ABSTRACT
HLA-identical bone marrow or stem cell transplantation from a sibling is the preferred treatment for patients with
chronic myelogenous leukemia, bone marrow failure syndromes, relapsed acute leukemia, and specific inborn
errors of metabolism. Several groups have shown that granulocyte colony-stimulating factor (G-CSF)–mobilized
peripheral blood progenitor cells (PBPCs) obtained from HLA-matched siblings are effective in reconstitution of
marrow function after marrow ablative conditioning therapy. To evaluate whether G-CSF treatment before bone
marrow harvest leads to enhanced recovery of PBPC counts and recovery from limited graft-versus-host disease
(GVHD), we assessed the outcome of a sequential cohort of patients treated identically and then given either G-
CSF–mobilized PBPCs or G-CSF–stimulated bone marrow from HLA-identical siblings. We show that the time to
neutrophil engraftment is identical in the 2 cohorts, whereas platelet engraftment is earlier with the use of PBPCs.
The incidence of acute GVHD was decreased, and that of chronic GVHD significantly decreased, in the group
receiving bone marrow. Overall survival was not different between the 2 groups. Thus, G-CSF–stimulated bone
marrow offers a source of stem cells that allows for early neutrophil engraftment with a decreased risk of GVHD.
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ing G-CSF–stimulated bone marrow or G-CSF–mobilized
PBPCs [10]. Furthermore, previous investigators have shown
that G-CSF has an impact on the function of alloreactive
T cells by several mechanisms, which include T helper 2
(Th2) polarization, alterations in cytokine production by
antigen-presenting cells, and changes in CD28/CD80 signal-
ing [11-14]. Thus, we have undertaken a series of studies to
investigate the time to engraftment, incidence of GVHD,
and overall survival in 2 cohorts of patients undergoing
allogeneic transplantation. The 2 cohorts were treated
identically except for the receipt of either G-CSF–mobilized
PBPCs or G-CSF–stimulated bone marrow.
MATERIALS AND METHODS
Study Protocol
Patients ages 12 to 55 years were eligible to participate in
the 2 trials. Eligible patients were enrolled from patients
referred to the Bone Marrow Transplantation Clinic at the
University of North Carolina Hospitals. All patients were
enrolled after discussion of the potential risks and beneﬁts of
the procedures. The studies were approved by the Commit-
tee on the Protection of the Rights of Human Subjects at the
University of North Carolina. Patient accrual was initiated in
February 1994 and terminated in December 1998.
The study was performed as 2 sequential nonrandomized
studies. Patients with an HLA-identical sibling and acute lym-
phoblastic leukemia (ALL) or acute myelogenous leukemia
(AML) in second remission or beyond or having high-risk fea-
tures in ﬁrst complete remission (CR1), multiple myeloma,
recurrent or refractory non-Hodgkin’s lymphoma (NHL),
Hodgkin’s disease, or chronic myelogenous leukemia (CML)
were eligible. Patients were excluded from the trials if the cre-
atinine clearance was <60 mL/min, ejection fraction <50%
using resting ventriculogram or echocardiogram, or carbon
monoxide diffusion capacity (DLCO) <50%. All patients who
entered the trial were negative for hepatitis surface antigen
and antibodies to human immunodeficiency virus (HIV).
HLA typing for class I alleles was performed using serological
methods at the University of North Carolina Hospitals. Class
II typing was performed using DNA analysis by sequence-spe-
ciﬁc oligonucleotide primers.
Donor Treatment
All donors received 10 µg/kg G-CSF for 4 days. On the
ﬁfth day, donors underwent either leukapheresis using a Cobe
Spectra or Fresenious AS104 machine or bone marrow har-
vest. Ten to 15 L blood was processed, and the leukapheresis
was continued until at least 5 × 106 CD34+ cells were
obtained. The median number of collections performed was 2
(range, 1-4). Bone marrow was collected to a target volume of
18 mL/kg recipient body weight, with approximately 5 mL
bone marrow aspirated from each site. PBPC products were
stored frozen in liquid nitrogen until the day of infusion.
Treatment and Supportive Care
All patients were treated prophylactically with trimetho-
prim/sulfamethoxazole, fluconazole, and ciprofloxacin as
described [15]. Intravenous antibiotics were administered for
fevers >38.3°C. Patients seropositive for herpes simplex virus
(HSV) received 200 mg acyclovir 3 times a day. All cyto-
megalovirus (CMV)-seronegative recipients who received
seropositive grafts were treated with ganciclovir starting at
day 21 until approximately day 100. All other patients were
screened by CMV antigen tests and treated if positive.
Patients with grade II or higher aGVHD were treated with
2 mg/kg intravenous 6-methylpredisolone and were routinely
given ganciclovir as prophylaxis. Packed red blood cells were
transfused if the morning hematocrit was <25%. Platelets
were administered for a platelet count of ≤10,000/mm3.
All nonmyeloma patients were conditioned with busul-
fan 16 mg/kg and cyclophosphamide 120 mg/kg as reported
[16]. Patients with multiple myeloma received busulfan
14 mg/kg in addition to the cyclophosphamide [17].
GVHD prophylaxis used short-course methotrexate
(15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and
cyclosporine (administered to maintain trough levels
between 250 and 350 ng/mL). Acute GVHD was graded as
reported [18]. G-CSF (300 µg subcutaneously) was adminis-
tered to 2 recipients of G-CSF–stimulated bone marrow,
1 at day 9 and 1 at day 17 after marrow infusion.
Outcome
Engraftment of neutrophils was deﬁned to be the ﬁrst of
3 consecutive days with a neutrophil count >500 × 109/L.
Platelet engraftment was deﬁned as the ﬁrst of 10 consecu-
tive days of platelets >20,000 × 109/L without transfusion.
Patients with AML or ALL in ﬁrst remission, NHL respon-
sive to salvage chemotherapy, and CML in chronic phase
were considered standard risk. All other patients were in the
high-risk cohort.
Flow Cytometry
Cell counts were adjusted to 1 × 107 cells/mL in phos-
phate-buffered saline. All cells were blocked for 10 minutes
using 5% human AB serum. Cells were stained for 15 minutes
with the following monoclonal antibodies (Becton Dickinson,
San Jose, CA): ﬂuorescein isothiocyanate (FITC)-conjugated
anti-CD3, anti-CD34, and immunoglobulin (Ig) G1 con-
trol; phycoerythrin (PE)-conjugated anti-CD4, anti-CD8α,
anti-CD14, anti-CD16, anti-CD19, anti-CD33, anti-CD38,
and IgG1 control; and Texas red–conjugated anti-CD45.
Three-color ﬂow cytometry was performed, and 25,000 to
100,000 events were analyzed using a FACScan ﬂow cytome-
ter and CellQuest Software (Becton Dickinson). The total
number of cells in each lineage was determined by multiply-
ing the total number of cells by the percentage derived from
the ﬂow histograms for the speciﬁc antibody used.
Statistics
The study was designed to show a 2-day earlier engraft-
ment of neutrophils in patients receiving G-CSF–mobilized
PBPCs compared with G-CSF–stimulated bone marrow.
With an estimated SD of 2.25 days for the median time to
neutrophil engraftment for the 2 groups, the inclusion of
21 patients in each group allowed for an 80% power to
detect this difference with an α error of ≤0.05. The group
receiving bone marrow was increased to 26 patients, which
gave the study a power of 85% to detect this difference.
Data were censored at the time of death or last follow-up,
which was July 15, 1999. Survival curves were determined
using the method of Kaplan and Meier [19]. Group compar-
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isons were performed using either Mann Whitney log rank
test or Student t test. Analysis of differences in the cause-of-
death was performed using Fisher exact test. All tests were
2-tailed. P values ≤ .05 were considered signiﬁcant.
RESULTS
Patient Characteristics
The characteristics of the patients receiving PBPC trans-
plant and the patients receiving bone marrow transplant are
given in Table 1. Both groups were equally balanced for type
of disease and the number of patients in each risk group.
There was a significant difference in the mean age of the
recipients (P = .02) and donors (P = .008), which favored a
decreased risk for grades II to IV GVHD in the group receiv-
ing PBPCs (mean age for recipients and donors 37) compared
with bone marrow (mean age for recipients 44 and for donors
45). A significant difference was also found in the ratio of
males and females between groups (P = .006), with a greater
number of males in the cohort that received G-CSF–stimu-
lated bone marrow. The median follow-up for the group that
received PBPCs was 887 days, and 367 days for the group
receiving G-CSF–stimulated bone marrow. The difference in
follow-up, which was due to the sequential nature of the
treatments, was statistically signiﬁcant (P = .008). Complica-
tions in the donors were strictly limited to bone pain and
headache, which required therapy with either acetaminophen
or oxycodone in the majority of donors. Platelet counts
decreased in the majority of donors giving PBPCs but did not
decrease below 20,000/mm3 and the decrease was not associ-
ated with clinical bleeding or the need for transfusion [20].
Donors underwent a median of 2 leukapheresis procedures.
Engraftment
The data for engraftment of white blood cells, platelets,
and transfusion support are presented in Table 2. The
median time to a neutrophil recovery >500 × 109/L was
17 days (range, 12-28 days) for patients receiving PBPCs and
16 days (range, 12-27 days) for patients receiving bone mar-
row. The median time to platelet recovery >20,000 × 109/L
without transfusion was 13 days (range, 0-65 days) for the
patients receiving PBPCs and 16 days (range, 9-68 days) for
the patients receiving bone marrow. There was no signiﬁcant
difference in the time to neutrophil engraftment (P = .90);
however, there was a strong trend toward earlier platelet
engraftment in the cohort receiving PBPCs (P = .06). There
were no differences in the mean number of red blood cell or
platelet transfusions during admission for the PBPC cohort
(7.7 ± 1.1 red blood cell units, P = .30; 5.7 ± 1.3 platelet units,
P = .80) compared with the bone marrow cohort (6.3 ± 0.9 red
blood cell units; 5.8 ± 1.2 platelet units).
Two recipients who received G-CSF–stimulated bone
marrow were treated with G-CSF after marrow infusion.
One patient, treated on day 9, received G-CSF because of
significant renal impairment from veno-occlusive disease
complicated by treatment with amphotericin B because of
neutropenic fever. Our protocol stipulated that patients
with a neutrophil count <500/mm3 receive G-CSF starting
on day 17 after marrow infusion. The second patient
received G-CSF on day 17 because of a neutrophil count of
200/mm3 on that day. The time to engraftment did not dif-
fer when the group that received G-CSF–stimulated mar-
row was evaluated without these 2 patients (median day 16
with or without the 2 patients).
Phenotypic Analysis of PBPC and Bone Marrow
Products
Using flow cytometry, we analyzed the number of
T lymphocytes and CD34+ progenitor cells infused in the
PBPC and bone marrow fractions. These data are shown in
Table 2. The mean number of T cells infused in the
Table 1. Patient Characteristics*
PBPCs Bone Marrow
n 20 26
Age, y† 37 (13-52) 44 (29-55)
Sex‡
Male 8 18
Female 12 8
Race
Caucasian 13 20
African American 7 6
Diagnosis
CML CP 9 9
CML CP2 0 1
AML 4 5
ALL 0 2
NHL 1 5
Myeloma 5 4
HD 1 0
Risk
Standard 11 15
High 9 11
Female/Male Donor/Recipient 1/20 5/26
Age§ 37 (range 15-55) 45 (range 32-54)
*Data are mean (range) or n. PBPCs indicates peripheral blood pro-
genitor cells; CML, chronic myelogenous leukemia; CP, chronic phase;
AML, acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; NHL, non-Hodgkin’s lymphoma; HD, Hodgkin’s disease.
†P = .02.
‡P = .006.
§P = .008.
Table 2. Engraftment Characteristics*
PBPCs Bone Marrow
Absolute neutrophil 17 (12-28) 16 (12-27)
count >500/mm3, d
Platelets >20,000/mm3, d 13 (0-65)† 16 (9-68)
Red blood cells
Transfusions 7.7 ± 1.1 6.3 ± 0.9
Platelet transfusions 5.7 ± 1.3 5.8 ± 1.2
CD3, × 106 cells/kg 54 ± 18 (15-85)‡ 4.0 ± 5.1 (0.08-25)
CD34, × 106 cells/kg 6.6 ± 0.8 (5.2-8.3)‡ 1.6 ± 0.6 (0.6-2.8)
*Data are mean (range), mean ± SD, or mean ± SD (range). PBPCs
indicates peripheral blood progenitor cells.
†P = .06.
‡P < .001.
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patients receiving PBPCs was 5.4 × 107 cells/kg; by con-
trast, the mean number of T cells infused in patients receiv-
ing bone marrow was 4 × 106/kg (P < .001). The mean
number of CD34+ cells infused was 6.6 × 106/kg for the
patients receiving PBPCs and 1.6 × 106/kg for the patients
receiving bone marrow (P < .001).
Overall and Relapse-Free Survival
The differences in survival as a function of the product
received are shown in Figure 1. There was a significant
trend for an improved survival at day 100 posttransplanta-
tion for the group receiving PBPCs (100%) compared with
the group receiving bone marrow (81%) (P = .059). Actuar-
ial survival for the 2 groups at 24 months posttransplanta-
tion was 60% for patients receiving PBPCs compared with
54% for patients receiving bone marrow. This difference
was not statistically significant (P = .90). When we sepa-
rated patients into standard and high-risk groups, we
identified trends in the outcome of the high-risk group
dependent on the type of transplant. Patients in the high-
risk PBPC group (Figure 1B) had a slight trend toward
improved survival (47%) compared with the high-risk bone
marrow group (22%; P = .20). However, the small number
of patients in each group and the disparate follow-up lim-
ited the ability to draw ﬁrm conclusions from this analysis.
At this time, we have not observed a signiﬁcant difference
in the outcome in the standard-risk group as a function of
the product infused (P = .80) (Figure 1C).
The causes of death in the patients receiving PBPCs or
bone marrow are presented in Table 3. For the group of
patients receiving PBSCs, infections were due to group A
streptococci (1), Streptococcus pneumoniae (2), Pseudomonas
aeruginosa (1), Escherichia coli (1), and unknown (1).
Graft-Versus-Host Disease
The incidences of grades II to IV acute and chronic
GVHD as a function of the product infused are shown in
Figures 2 and 3 and Table 4. At 90 days posttransplantation,
there was a strong trend toward an increased incidence of
aGVHD in the cohort that received PBPCs (60%) com-
pared with marrow (27%; P = .07). At 1 year posttransplan-
tation, we found a significantly increased incidence of
cGVHD in PBPC patients (68%) compared with bone mar-
row patients (37%; P = .049).
DISCUSSION
We have investigated the outcome for patients who were
treated identically with the exception of receiving either
G-CSF–mobilized PBPCs or G-CSF–stimulated bone mar-
row. We have found that patients who received G-CSF–
stimulated bone marrow had a similar time to neutrophil
engraftment and a similar use of red blood cell and platelet
products after transplantation. We observed a slightly pro-
longed time to platelet engraftment in the cohort that
received marrow compared with PBPCs. There was a statis-
tically signiﬁcant decreased incidence of cGVHD after the
use of G-CSF–stimulated bone marrow compared with
PBPC and a nonsigniﬁcant trend for a decreased incidence of
aGVHD. The actuarial survival for recipients of PBPCs and
bone marrow was similar at 24 months posttransplantation.
Figure 1. Actuarial overall survival of patients receiving either periph-
eral blood progenitor cells or bone marrow as a source of stem cells. A.
All patients. B. High-risk patients. C. Standard-risk patients. G-CSF
indicates granulocyte colony-stimulating factor.
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One of the initial positive attributes of the use of G-CSF–
mobilized PBPCs was earlier neutrophil and platelet engraft-
ment. Previous investigators have shown that patients who
receive G-CSF–mobilized PBPCs have an earlier time to
engraftment than those who receive nonstimulated bone mar-
row [2,3,5,6,21]. In several studies using nonmanipulated bone
marrow, the median time to neutrophil engraftment in indi-
viduals receiving cyclosporine and short-course methotrexate
was 21 to 24 days posttransplantation, and the median time to
a platelet count of 20,000/mm3 without transfusion was 24 to
27 days [22-26]. Thus, the use of G-CSF–stimulated bone
marrow in this report resulted in earlier engraftment of both
neutrophils and platelets compared with historical control
patients given nonmanipulated bone marrow.
The time to engraftment of neutrophils in individuals
receiving PBPCs in this study was slightly longer than that
of previous cohorts receiving PBPCs. The median time to
neutrophil engraftment in previous series has been 12 to
13 days postinfusion. There are several possibilities for the
longer time to engraftment. We did not routinely adminis-
ter growth factors to our patients, but other centers have
administered growth factors after PBPC infusion to improve
the time to neutrophil recovery [4]. The group in Seattle
infused PBPCs without prior freezing [21]. As all of the
PBPCs given in this study were frozen, the delay in engraft-
ment of neutrophils could be due to the effect of freezing on
progenitor cell number or function. Other groups have used
either a different conditioning regimen or not used
methotrexate as GVHD prophylaxis [2]. Both of these fac-
tors can inﬂuence the time to engraftment.
One recent report treated patients in an identical fash-
ion as in this series [8]. Although we infused a greater num-
ber of CD34+ cells, 6.6 × 106/kg versus 5.4 × 106/kg, the
median time to neutrophil engraftment in our series was still
longer than that reported by Ustun et al. [8]. Interestingly,
the 13-day time to platelet engraftment after administration
of PBPCs found here was similar to those in all other trials.
As has been shown previously, the number of T cells was
much greater in the G-CSF–mobilized PBPCs than in the
G-CSF–stimulated bone marrow. Previous reports using his-
torical controls have shown that despite the increased number
of T cells in the product, the incidence of grades II to IV
aGVHD was often not greater in PBPC recipients compared
with bone marrow recipients. We found that the incidence of
grades II to IV aGVHD was increased in patients who
received PBPCs (60%) compared with bone marrow (27%),
and this difference approached statistical signiﬁcance. The
longer time to neutrophil engraftment seen in this study may
be 1 cause for the increased incidence of GVHD compared
with prior trials using PBPCs. In animal models, there is a
strong relationship between the release of endotoxin and the
magnitude of aGVHD, suggesting that earlier recovery of
neutrophils may decrease infectious complications and the
incidence of GVHD [27-29]. Additionally, the group at M.D.
Anderson Cancer Center (Houston, TX) has recently
reported on the outcome of 160 recipients of allogeneic
PBPCs [30]. Using regression residual statistics, they found a
sharp increased risk of GVHD after the administration of
between 6.3 × 106 and 10.0 × 106 CD34+ cells/kg. For recipi-
ents of G-CSF–stimulated PBPCs in this series, 17 of 20 (85%)
received between 6.3 × 106 and 10.0 × 106 CD34+ cells/kg. This
may have contributed to the increased risk of GVHD for
recipients of G-CSF–stimulated PBPC in this study. Very few
of the group that received PBPCs in this report received more
than 7.5 × 106 CD34+ cells/kg. Thus, we were unable to verify
data showing an increased incidence of aGVHD for recipients
of more than 8.2 × 106 CD34+ cells/kg [30].
Table 3. Reasons for Death*
PBPCs Bone Marrow
High-Risk Standard-Risk High-Risk Standard-Risk
Relapse 3 0 5 0
Treatment-related mortality 1 0 0 2
Acute GVHD 0 0 0 1
Late infections/chronic GVHD 1 5 1 2
Other† 1 0 1 0
Death/total patients 6/9 5/11 7/11 5/15
*PBPCs indicates peripheral blood progenitor cells; GVHD, graft-versus-host-disease.
†One patient who received PBPCs died after a myocardial infarction that was thought to be secondary to previous radiation treatment. One patient
who received bone marrow discontinued immunosuppressive medications without a physician’s approval and presented with refractory GVHD that
did not respond to treatment.
Figure 2. Incidence of grade II to IV acute graft-versus-host disease
for patients receiving peripheral blood progenitor cells or bone mar-
row. G-CSF indicates granulocyte colony-stimulating factor.
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We found an increased incidence of cGVHD in the
group that received PBPCs, which is consistent with previ-
ous observations [6,7]. Although the median follow-up for
the group receiving bone marrow was more than 1 year
posttransplantation, it was signiﬁcantly shorter than that of
the group receiving PBPCs. This difference may have
inﬂuenced the decreased incidence of cGVHD in patients
receiving bone marrow. The decreased incidence of
cGVHD using G-CSF–stimulated bone marrow compared
with G-CSF–mobilized PBPCs will need to be verified in
randomized clinical trials and with longer follow-up. 
We did not find a difference in overall survival of
patients as a function of the type of product infused. The
number of high-risk patients in the 2 series was small, and
we did not detect differences in the relapse rate for this
group as a function of the product received (33% PBPCs
versus 50% bone marrow; P = .65), despite the significantly
increased incidence of cGVHD in high-risk patients. We
did observe a trend for late infectious deaths in the setting
of cGVHD for recipients of PBPCs versus marrow. For
standard-risk patients who survived past day 120, the inci-
dence of late infectious deaths was 45% for recipients of
PBPCs versus 15% for patients receiving bone marrow 
(P = .18). If this trend were to continue, there would be an
improved outcome in patients in the standard-risk group
given G-CSF–stimulated bone marrow due to the late
infectious deaths in the cohort receiving PBPCs. In the
standard-risk setting, where the risk of relapse is low, the
greater incidence of infectious complications associated
with cGVHD may outweigh the benefits of the graft-ver-
sus-tumor response. If this is true, it suggests an approach
to management of transplant patients in which the risk of
recurrent disease would help dictate the type of product
infused.
Two previous reports have described the outcome of
small numbers of patients with limited follow-up given
G-CSF–stimulated bone marrow in the allogeneic setting.
Isola et al. [31] described the treatment of 10 patients who
were treated with cyclophosphamide 120 mg/kg and (pre-
dominantly) 1500 cGy total body irradiation (TBI). The
primary diagnosis was CML in ﬁrst chronic phase (n = 4).
GVHD prophylaxis was a combination of cyclosporine and
methotrexate or cyclosporine and prednisone. Despite a
smaller volume of bone marrow, the mean number of
CD34+ cells per kg was significantly higher in this cohort
(9.4 × 106/kg) than in our patients (1.6 × 106/kg), which
may be explained by the bone marrow having been col-
lected earlier after the administration of G-CSF. Compared
with patients described in this series, the median time to
neutrophil engraftment was decreased by 2 days, but inter-
estingly, the time to platelet engraftment was increased by
4 days. The incidence of grades II to IV GVHD was 0% in
the 6 patients who lived past day 100.
Mavroudis et al. [9] had previously reported on the out-
come of 12 patients who received T-cell–depleted G-CSF–
stimulated bone marrow from HLA-identical donors. The
conditioning regimen employed was cyclophosphamide
(60 mg/kg per day for 2 days) and TBI (up to 1360 cGy).
Approximately 1200 mL bone marrow was harvested and
selected using a CD34– selection column. In that study,
4 patients developed pancytopenia after initial engraftment.
The late incidence of graft failure observed with CD34–-
selected, G-CSF–stimulated bone marrow was not found in
either our cohort of patients or that described by Isola et al.
[31]. This difference may relate to the lack of T-cell deple-
tion in our patients and those of Isola et al., as we infused a
slightly decreased number of CD34+ cells per kg (1.6 × 106
CD34 versus 1.8 × 106/kg) compared with Mavroudis et al.
The 33% incidence of grades II to IV aGVHD described
by Mavroudis et al. was similar to that found here (27%),
suggesting little benefit from CD34– selection in the pre-
vention of aGVHD after receipt of G-CSF–stimulated
bone marrow.
In summary, we have found that G-CSF–stimulated
bone marrow offers the early engraftment of neutrophils
that is seen with PBPCs, with a decreased risk of both acute
and chronic GVHD. These observations, however, are pre-
liminary and are being veriﬁed in randomized clinical trials
[1]. If these ﬁndings are veriﬁed, in the future, the type of
product infused in the allogeneic setting may be stratified
based on the risk of relapse. G-CSF–stimulated bone mar-
row may be preferable for patients with CML in chronic
phase and patients with AML or ALL in first remission,
where the lower incidence of GVHD would factor more
favorably than the risk of recurrent disease.
Table 4. Assessment of Graft-Versus-Host Disease*
Acute GVHD PBPCs Bone Marrow
Grades II-IV 12/20 (60%) 7/26 (27%)
Grades III-IV 4/20 (20%) 2/26 (8%)
Skin 10/12 (83%) 6/7 (86%)
Gastrointestinal Tract 4/12 (33%) 4/7 (57%)
Liver 0/12 (0%) 2/7 (29%)
*The percentages for involvement of the different organs with graft-
versus-host disease (GVHD) are determined by dividing the number of
patients with documented GVHD at that site by the total number with
GVHD. PBPCs indicates peripheral blood progenitor cells.
Figure 3. Incidence of chronic graft-versus-host disease for patients
receiving peripheral blood progenitor cells or bone marrow. G-CSF
indicates granulocyte colony-stimulating factor.
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